click
Contact

Tag: LQ036

Novamab Announces NMPA CDE Approval of IND for LQ036, the World’s First Inhaled Nanobody for Moderate-to-Severe Asthma

Novamab has announced that the CDE of the NMPA has approved its IND application for LQ036, the world’s first inhaled nanobody for moderate to severe asthma. LQ036 is a recombinant anti-IL-4Rα single-domain antibody nebulizing solution produced in Pichia pastoris. Medicilon leveraged its dedicated Inhalation Formulation R&D Platform to deliver high quality services for the inhalation […]

Contact

Search Medicilon

Medicilion Congratulates MediLink Therapeutics on Licensing B7H3 ADC to Roche

Medicilon Signs Five-Year Strategic Cooperation Agreement with BioPartners X to Jointly Promote Innovative Drug R&D

Read more
Medicilion Congratulates MediLink Therapeutics on Licensing B7H3 ADC to Roche

Medicilon and Protheragen Forge Strategic Partnership to Build a Collaborative “Project + Platform” Model

Read more
Medicilion Congratulates MediLink Therapeutics on Licensing B7H3 ADC to Roche

AOC Development: Conjugation Site Selection, DAR Control & In Vitro Testing | Full Webinar

Read more

Contact Medicilon

Name(Required)
Address(Required)